After strong preclinical testing results, Cybin is looking to advance CYB003 into a Plase 1/2a clinical trial, estimated for mid-2022.
Exploring the companies and themes that make up this emerging and exciting new sector
Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application
Enveric Biosciences announces that it has expanded on its psychedelic drug R&D pipeline along with filing a new patent application.
The War AGAINST Mental Health: 50 Years Of Failure And Corruption
For 50 years Western governments have relentlessly undermined the mental health of their citizens while also criminalizing the only effective drugs for treating mental health.
Awakn Life Sciences Announces Closing of Private Placement
Awakn Life Sciences announces closing a a CAD $3.25 million private placement, with units priced at $1.60 along with a half-warrant with an exercise price of $2.20.
Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
Wesana Health reports positive treatment results in combining traditional antidepressants with psilocybin-based therapy.
Revitalist Launches UNIT Initiative Working With Veteran and First Responder Non-Profits Across the United States Creating Nationwide Guidelines
Revitalist Lifestyle and Wellness announces a new initiative focusing on providing access to mental health therapies for veterans and first-responders.
Red Light Holland Successfully Imports Psilocybin iMicrodose Packs into St. Vincent and the Grenadines Under a First-Ever Authorized Import Approval Process by the Country's Bureau of Standards and the Ministry of Health
Red Light Holland announces the first-ever import of psilocybin mushrooms into St. Vincent and the Grenadines.
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
Awaken receives regulatory approval to begin ketamine-based therapies in its flagship London mental health clinic.
MINDCURE Provides Update on Strategic Review
MINDCURE announces the completion of its strategic review and new cost saving measures.
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
Novamind announces it will most MindMed's Phase IIb clinical trial of LSD-based therapy for generalized anxiety disorder (GAD).
Ketamine Wellness Centers (KWC) Announces Grand Opening of Reno Clinic
Ketamine Wellness Centers, a subsidiary of Delic Holdings, announces the grand opening of its 13th ketamine clinic.